Correlation of serum immunoglobulin free light chain quantification with urinary Bence Jones protein in light chain myeloma.
Renal failure occurs in ~25% of myeloma patients, and there is some renal pathology in more than one-half (1, 5, 6). The number of patients with renal disease varies considerably depending on the criteria used to define renal impairment. Serum creatinine concentrations remain in the reference interval until the glomerular filtration rate is reduced by almost 50%; therefore, the data obtained with blood creatinine concentrations most likely underestimate the incidence of renal involvement in myeloma. Data using the estimated creatinine clearance rate (7), which takes into account various variables, including patient age, weight, and gender, indicate that approximately one-half of patients have renal insufficiency at the time of diagnosis (5). The nature of the M component is also associated with the prevalence of renal disease (5, 8, 9). In light chain myeloma, 65% of patients have impaired renal function at the time of diagnosis when estimated creatinine clearance is used as the variable (5). The incidence of renal dysfunction is greater in patients with compounding factors, such as hypercalcemia and advanced disease (5, 8, 9). Although there are numerous contributing factors for renal dysfunction in myeloma, the primary among them is the filtration of large quantities of light chains by the glomeruli (10, 11), which produces a huge reabsorptive load on the proximal tubules.
Tubular dysfunction is seen in 98% of patients with Bence Jones proteinuria >1 g/24 h (9). However, tubular damage associated with the excretion of light chains is almost always present (10). Usually, because light chains are of low molecular weight (~25 000), they are readily filtered by the glomeruli, reabsorbed in the renal tubules, and catabolized. If the filtered load is excessive, as occurs in LCMM, this reabsorptive capacity is exceeded and free light chains appear in the urine, where they have also been concentrated by physiologic renal tubular water reabsorption. Tubular damage results either directly from light chain toxic effects or indirectly from the release of intracellular lysosomal enzymes (10). The proteinuria that involves essentially only light chains does not cause hyperalbuminuria. Usually, there is very little albumin in the urine because glomerular function is intact. Patients with myeloma may present with acute renal failure at the time of diagnosis, or acute renal failure may manifest itself during the course of disease. In a study done at Oxford, it was noted that among patients admitted for acute renal failure, there was an excess of LCMMs and IgD myelomas (10, 12).
Various laboratory markers are used for the diagnosis and monitoring of patients with multiple myeloma. Among the protein components, serum M peaks and/or BJPs are identifiable in virtually all patients with the disease (13-16).
A major pitfall in the measurement of urinary light chains is that dipsticks for detecting proteinuria are unreliable in recognizing free light chains. Additionally, the conventional tests used for detecting BJPs are falsely negative in approximately one-half of patients with LCMM. Because of the high urinary concentration of light chains, 24-h urine collections have traditionally been used for the detection of light chains in patients with suspected multiple myeloma. Moreover, the amount of light chain excreted in the urine often correlates with disease progression. However, 24-h urine collections are cumbersome and are prone to inaccuracies because of incorrect collection, and measurement of urinary light chains by electrophoresis is difficult. It is therefore clinically relevant to develop a modality to measure free light chains in the serum as a viable alternative to measuring BJPs to follow the course of disease in this group of patients.
As part of another research project, a registry of 29 500 dysproteinemic patients identified at the Mayo Clinic from 1960 to the present is maintained. From this registry, 28 patients with LCMM were selected for this analysis. This study was conducted with approval from the Institutional Review Board. A previously described nephelometric assay, performed using a Dade Behring BNII nephelometer [Ref. (17) and Katzmann JA, Clark RJ, Abraham RS, Bryant SC, Lymp JF, Bradwell AR, et al. Serum diagnostic and reference ranges for free [kappa] and free [lambda] immunoglobulin light chains: age dependence and relative sensitivity for detection of monoclonal light chains, submitted for publication], was used to quantify free immunoglobulin light chains (FLCs) in the sera of these patients. This method uses antibodies (Freelite[R]; The Binding Site, Ltd.) specific for [kappa] and [lambda] light chains in free form, not bound to the heavy chain (17).
For most patients, data from at least two to three different time intervals were analyzed. Of the 28 LCMM patients in the study, 9 were positive for [kappa] light chain and 19 for [lambda] light chain. All of these patients had a monoclonal light chain detected by immunofixation in the serum and urine. Although all the patients had a M peak in the urine, only 3 of 9 [kappa] patients and 13 of 19 [lambda] patients had a M peak in the serum. We wished to determine whether serum FLC quantification could serve as a surrogate for urinary M-protein measurements in this group of patients. In the [kappa] subgroup, of the nine patients, eight (89%) had increased [kappa] FLCs in the serum. The median [kappa] FLC was 699 mg/L (reference interval, 2-11.2 mg/L). All nine [kappa] patients had abnormally increased free light chain [kappa]/[lambda] (FLC K/L) ratios, with a median value of 248 (reference interval, 0.09-0.89). In the [lambda] group, all 19 (100%) patients had both increased [lambda] FLCs and abnormally decreased FLC K/L ratios in the serum, with median values of 1390 mg/L (reference interval, 6.8-25.2 mg/L) and 0.005 (reference interval, 0.09-0.89), respectively. The utility of the serum FLC K/L ratio for detecting monoclonality was evaluated by measuring FLC concentrations in the sera of seven patients who had increased urinary protein unrelated to a monoclonal gammopathy. These patients had renal disease secondary to systemic lupus erythematosus, glomerulonephritis, or renal disease of unknown etiology. Six of seven patients had serum [kappa] and [lambda] FLC concentrations within the respective reference intervals. The single abnormal result was an increased serum [lambda] FLC. The FLC K/L ratios, however, were within the reference interval for all seven patients, suggesting that excess [kappa] or [lambda] serum FLC is a marker in the context of monoclonal gammopathies.
Results for sequential serum FLCs and 24-h urinary monoclonal protein were compared for a representative [kappa] and a representative [lambda] LCMM patient (Fig. 1). These two patients illustrate that the serum FLC and the 24-h urinary M-protein concentrations behave in a coordinated fashion. However, the absolute value for urinary M protein could not be correlated with the absolute value for serum FLC, as evidenced by the initial measurements for 24-h urinary M protein and serum FLC (Table 1).
[FIGURE 1 OMITTED]
In light of this information, we were interested in evaluating whether changes in urinary M-protein concentrations could be predicted by serum FLC. A random-effects model was fit to these data to estimate the correlation between changes in urinary M protein and serum FLC and to test whether the correlation was significantly different from zero (18). The dependent variable was [log.sub.10](urinary M protein), whereas the independent variable was [log.sub.10](serum FLC). Log transformations were made to both the dependent and independent variables to improve the model fit.
Changes in urinary M protein correlated strongly with changes in serum FLC concentrations when we used the random-effects model (P = 0.0001). In other words, although serum FLC does not quantitatively match urinary M-protein concentrations, changes in serum FLC over a period of time correlate with changes in the amounts of 24-h urinary M protein for an individual patient.
It appears, therefore, that the quantification of FLCs in serum by nephelometry correlates linearly on a log-log scale with changes in urinary FLC excretion. This correlation suggests that serum measurements may provide a logical and feasible alternative to 24-h urine collections in monitoring patients with LCMM.
This study was supported in part by Grant CA 62242 from the National Cancer Institute. We also wish to acknowledge Dr. A. R. Bradwell and The Binding Site, Ltd (Birmingham, United Kingdom) for providing the FLC reagents for analysis.
(1.) Kyle RA. Multiple myeloma. Review of 869 cases. Mayo Clin Proc 1975;50: 29-40.
(2.) Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998;91:3-21.
(3.) Tricot G. New insights into the role of microenvironment in multiple myeloma. Lancet 2000;355:248-50.
(4.) Kyle RA, Katzmann, JA. Immunochemical characterization of immunoglobulins. In: Rose NR, Conway de Macario E, Folds JD, Lane HC, Nakamura RM, eds. Manual of clinical laboratory immunology, 5th ed. Washington: American Society of Microbiology, 1997:156-76.
(5.) Knudsen LM, Hippe E, Hjorth M, Holmberg E, Westin J. Renal function in newly diagnosed multiple myeloma--a demographic study of 1353 patients. Eur J Hematol 1994;53:207-12.
(6.) MRC Working Party on Leukemia in Adults. Analysis and management of renal failure in the fourth MRC myelomatosis trial. Br Med J 1984;288: 1411-6.
(7.) Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
(8.) Alexanian R, Barlogie B, Dixon D. Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Intern Med 1990;150: 1693-5.
(9.) Cooper EH, Forbes MA, Crockson RA, MacLennan ICM. Proximal renal tubular function in myelomatosis: observations in the fourth MRC trial. J Clin Pathol 1984;37:852-8.
(10.) Winearls CG. Acute myeloma kidney. Kidney Int 1995;48:1347-61.
(11.) Sanders PW, Herrera GA. Monoclonal immunoglobulin light chain-related renal diseases. Semin Nephrol 1993;13:324-41.
(12.) Pasquali S, Casanova S, Zucchelli A, Zucchelli P. Long-term survival in patients with acute and severe renal failure due to multiple myeloma. Clin Nephrol 1990;34:247-54.
(13.) Farhangi M, Osserman EF. Biology, clinical patterns, and treatment of multiple myeloma and related plasma cell dyscrasias. In: Twomey JJ, Good RA, eds. The Immunopathology of lymphoreticular neoplasms, comprehensive immunology, Vol. 4. New York: Plenum Medical Book Company, 1978:641-719.
(14.) Franklin EC, Buxbaum J. Immunoglobulins in the normal state and in neoplasms of B cells. In: Twomey JJ, Good RA, eds. The immunopathology of lymphoreticular neoplasms, comprehensive immunology, Vol. 4. New York: Plenum Medical Book Company, 1978:361-90.
(15.) Osterland CK. Monoclonal gammopathies--their identification and biological significance. Clin Chim Acta 1989;180-1.
(16.) Sakurabayashi I, Kin K, Kawai T. Human IgA1 half molecules: clinical and immunologic features in a patient with multiple myeloma. Blood 1979;53: 269-78.
(17.) Bradwell AR, Carr-Smith HD, Mead GP, Tang LX, Showell PJ, Drayson MT, Drew R. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001;47:673-80.
(18.) Laird NM, Ware JH. Random-effects model for longitudinal data. Biometrics 1982;38:963-74.
Roshini S. Abraham,  Raynell J. Clark,  Sandra C. Bryant,  James F. Lymp,  Timothy Larson,  Robert A. Kyle, [1,4] and Jerry A. Katzmann  * ( Division of Clinical Biochemistry and Immunology,  Section of Biostatistics,  Division of Nephrology, and  Division of Hematology, Mayo Clinic, 200 1st St. SW, Rochester, MN 55905; * author for correspondence: fax 507-266-4088, e-mail firstname.lastname@example.org)
Table 1. Comparison of initial serum FLC (mg/L) and 24-h urine M-protein (g/24 h) values in 28 patients with LCMM. 24-h urine [kappa] M protein, FLC, (a) [lambda] Patients g/24 h mg/L FLC, mg/L [kappa] patients 1 0.33 22.6 12.3 2 2.25 4370 10.1 3 1.77 699 14.3 4 1.36 1390 5.6 5 1.81 693 1.2 6 0.10 276 1.1 7 0.03 2820 8.1 8 0.30 1230 9.8 9 1.31 351 5.1 [lambda] patients 10 0.29 10.4 235 11 1.53 1.0 1030 12 3.04 3.3 15 900 13 6.32 4.8 116 14 3.31 7.0 11 000 15 0.11 1.1 46.5 16 4.11 0.9 545 17 5.02 6.8 1390 18 1.23 7.2 1430 19 4.20 9.2 4690 20 1.46 3.1 71.8 21 7.14 1.2 65.4 22 10.81 6.9 2700 23 4.01 16.9 2360 24 6.48 10.5 1420 25 0.79 46.7 10 000 26 0.10 5.9 81.6 27 2.99 1.0 326 28 5.58 4.5 3570 (a) Reference intervals: [kappa] = 2-11.2 mg/L [lambda]; = 6.8-25.2 mg/L.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Technical Brief|
|Author:||Abraham, Roshini S.; Clark, Raynell J.; Bryant, Sandra C.; Lymp, James F.; Larson, Timothy; Kyle, Ro|
|Date:||Apr 1, 2002|
|Previous Article:||Accuracy of expected risk of down syndrome using the second-trimester triple test.|
|Next Article:||Genotyping of the apolipoprotein B R3500Q mutation using immobilized locked nucleic acid capture probes.|